Open AccessSevere allergic asthma: Does alexithymia interfere with omalizumab treatment outcome?
Author(s) -
Marta Liotta,
M. Liotta,
Salvatore Saitta,
L Ricciardi
Publication year - 2023
Publication title -
asian pacific journal of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 33
ISSN - 0125-877X
DOI - 10.12932/ap-040121-1031
Subject(s) - alexithymia , omalizumab , medicine , asthma , immunoglobulin e , quality of life (healthcare) , toronto alexithymia scale , gastroenterology , physical therapy , clinical psychology , immunology , antibody , nursing
Alexithymia is among psychological factors reported to interfere with asthma management. Severe allergic asthma (SAA) is characterized by uncontrolled asthma despite maximal standard pharmacological treatment which can benefit from an add-on treatment with Omalizumab, an anti-IgE monoclonal antibody.